Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05323825
Other study ID # UCAMCFE-00026
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 25, 2022
Est. completion date January 25, 2023

Study information

Verified date March 2022
Source Universidad Católica San Antonio de Murcia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single-center, randomized, double-blind, placebo-controlled clinical study with two study groups. One group will consume a product with functional ingredients and the other group will consume a placebo product. will consume a placebo product.


Description:

When individuals are included in the study they will be randomized in equal proportion to one of the 2 groups of the study. The randomization will be stratified by age taking into account 2 strata (1:1). The first stratum corresponds to an age range of 18 to 40 years and the second stratum to an age range of 41 to 60 years. The subject must consume the product for 8 weeks and will have a visit 4 weeks later as a follow-up of the study. At the visits the subject will perform a series of cognitive tests and the intestinal microbiota will be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date January 25, 2023
Est. primary completion date January 16, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Men and women aged 18-60 years. - Individuals with a diagnosis of mild-moderate stress according to the Cohen's perceived stress scale perceived stress scale (PSS-10). - Subjects with poor adherence to the Mediterranean diet according to the PREDIMED questionnaire (value below 9 points)*. - BMI between 19 and 30 kg/m2. Exclusion Criteria: - Present chronic and/or acute digestive pathologies that may interfere in the absorption of nutrients (inflammatory intestinal diseases, inflammatory bowel absorption of nutrients (inflammatory intestinal diseases, etc.), etc.) - Intake of probiotics and/or prebiotics in the four weeks prior to the inclusion in the study. - Individuals who are on antibiotic treatment or have completed an antibiotic treatment during the 30 days prior to inclusion in the study. - Vegan diet. - Being taking any type of supplementation that interacts with cognitive level in the 2 weeks prior to the start of the study. - Individuals who had taken or were taking any medications or supplementation for stress management, mood, or to induce sleep in the 2 weeks prior to the start of the study. - A history of allergic hypersensitivity or poor tolerance to any component of the products under study. - Consumption of 2 or more Standard Drink Units (UBE) daily or 17 weekly in women, or consume 4 or more UBE daily or 28 weekly in men. - Smoking and non-smoking subjects who have modified their nicotinic habits in the last 3 months. - Pregnant or lactating women. - Been participating or have participated in another clinical trial in the 2 months prior to the study to the study. - Unwillingness or inability to comply with the procedures of the clinical trial. - Subjects with any diagnosed psychiatric disorder. - Subjects whose condition makes them ineligible for the study in accordance with the criteria of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic
Fermented milk product containing a probiotic
Placebo
Product with identical characteristics to the experimental product.

Locations

Country Name City State
Spain Catholic University of Murcia Murcia

Sponsors (1)

Lead Sponsor Collaborator
Universidad Católica San Antonio de Murcia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cognitive performance COMPASS cognitive test panel Change in baseline cognitive performance after 8 weeks of consumption
Secondary Perceived Stress Scale PSS-14 test Day 1, at 4 and 8 weeks later
Secondary Mood profile POMS test Day 1, at 4 and 8 weeks later
Secondary Depression, Anxiety and Stress DASS21 test Day 1, at 4 and 8 weeks later
Secondary State of mind PANAS test Day 1, at 4 and 8 weeks later
Secondary Stress status using VAS scale Stress status on the day of the visit Day 1, at 4 and 8 weeks later
Secondary Sleep efficiency Measured by accelerometry, with Actigraph wGT3X-BT It will be measured for 3 days, before starting the consumption of the product, after 30 days of consumption and at the end of consumption (60 days).
Secondary Sleep quality Pittsburgh test Day 1, at 4 and 8 weeks later
Secondary Gut microbiota Evaluated with stool sample Day 1, at 4, 8 and 12 weeks later
Secondary Adverse events It will be evaluated at each of the visits and in the month of follow-up will be evaluated with a daily diary. At 4 weeks, 8 and 12 weeks after consumption
Secondary Concomitant medication The change in the use of medications will be evaluated. It will be evaluated at each of the visits and in the month of follow-up will be evaluated with a daily diary. Day 1, at 4, 8 and 12 weeks later
Secondary Dietary survey Three days will be evaluated (two weekdays and one weekend day). Day 1, at 4, 8 and 12 weeks later
Secondary Body weight Bioimpedance, in Kg. For this we will use a TANITA Day 1, at 8 weeks later
Secondary Liver safety variables It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L) It will be measured twice, once at baseline or at the end of the consumption after 8 weeks.
See also
  Status Clinical Trial Phase
Completed NCT05712005 - Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
Completed NCT05343208 - Effectiveness of Online Therapy to Prevent Burnout N/A
Active, not recruiting NCT05143294 - Conectar Jugando: Board Games in Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT05267730 - Conectar Jugando: Board Games in Rural Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT03987477 - Online Intervention to Modify Interpretation Biases in Depression N/A
Completed NCT03695003 - Cognitive Effects of Sage in Healthy Humans N/A
Completed NCT05075850 - Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03689348 - Acute and Chronic Effects of Avena Sativa on Cognition and Stress N/A
Active, not recruiting NCT05229705 - Exercise in Older Adults at Risk for Type 2 Diabetes N/A
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Terminated NCT03337282 - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Completed NCT03657537 - Effects of Ketone Bodies on Cognition in Type 2 Diabetes Phase 1
Completed NCT05543811 - The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive Pathology N/A
Recruiting NCT05699226 - Amplitude Titration to Improve ECT Clinical Outcomes N/A
Recruiting NCT05026541 - Resilience to Sleep Deprivation and Changes in Sleep Architecture in Shoonya Meditators N/A
Active, not recruiting NCT03255499 - Efficacy of the MovinCog Intervention in Children N/A
Not yet recruiting NCT06252376 - Effects of Blood Pressure on Cognition and Cerebral Hemodynamics in PD N/A